Konruns 康辰药业
30 significant filings since 29 May 2026: 1 on litigation, 19 on equity incentive and 9 on buyback, and 1 other kind. The latest, on 25 Sep 2026: 康辰药业关于涉及仲裁结果的公告.
自 29 May 2026 起有 30 份重大公告：litigation 1 份、equity incentive 19 份、buyback 9 份，另有 1 类。最新一份（25 Sep 2026）：康辰药业关于涉及仲裁结果的公告。
| FY2026 | FY2027 | |
|---|---|---|
| Now 当前 | 2 brokers | 2 brokers |
| 7 days ago | 1.16 | 1.24 |
| 30 days ago | 1.15 | 1.29 |
| 60 days ago | 1.17 | 1.30 |
| 90 days ago | 1.17 | 1.30 |
Consensus is the median of each broker's latest forecast from the 120 days before each date. With fewer than 3 brokers, the broker count is shown. 一致预期为各券商在该日期前 120 天内最新预测的中位数；不足 3 家时显示券商数。
Consensus moved from 1.30 in Sep 2024 to 1.17 in Jul 2026 (-10.0%). 一致预期从 Sep 2024 的 1.30 变为 Jul 2026 的 1.17 (-10.0%)。 The shaded band runs from the lowest to the highest broker forecast.
| FY2026 | FY2027 | |
|---|---|---|
| Last 30 days | ▲ 1 ▼ 0 = 1 | ▲ 0 ▼ 2 = 0 |
| Last 90 days | ▲ 1 ▼ 0 = 1 | ▲ 0 ▼ 2 = 0 |
Each broker's latest forecast is compared with its previous forecast for the same year. A move within 0.5% counts as unchanged. 每家券商的最新预测与其对同一年度的上一次预测比较，变动在 0.5% 以内视为不变。
| Year | Filed | Consensus | Brokers 券商 | Reported 实际 | Surprise 偏差 |
|---|---|---|---|---|---|
| FY2022 | 26 Apr 2023 | 0.85 | 4 | 0.65 | -24.0% |
Surprise is reported EPS against the consensus on the day before the annual report was filed. 偏差为实际每股收益与年报披露前一日一致预期之差。
A surprise needs at least 3 brokers forecasting in the 120 days before the filing. FY2025 had 0 and FY2024 had 1.